Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice

Laboratory Investigation

Volumn 90, Issue 8, 2010, Pages 1169-1178

  Yamaguchi, Kanji ^a   Itoh, Yoshito ^a   Yokomizo, Chihiro ^a   Nishimura, Takeshi ^a   Niimi, Toshihisa ^a   Fujii, Hideki ^a   Okanoue, Takeshi ^a,b   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

IL 6; MCD diet; NASH; SREBP 1; STAT3

Indexed keywords

ACTIN; ADENYLATE KINASE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; CATALASE; COLLAGEN; CYTOCHROME P450 2E1; FATTY ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; LIPID; METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN KINASE B; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DISEASE COURSE; FATTY ACID BLOOD LEVEL; FATTY LIVER; GENE EXPRESSION; INFLAMMATION; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VITAMIN DEFICIENCY;

ALANINE TRANSAMINASE; ANIMALS; CHOLINE; CHOLINE DEFICIENCY; DIET; FATTY LIVER; GENES; INTERLEUKIN-6; LIPID PEROXIDATION; LIVER; MALE; METHIONINE; MICE; MICE, INBRED C57BL; PPAR ALPHA; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 77955150888     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.75     Document Type: Article

References (41)

1. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Day CP, James OF. Steatohepatitis: a tale of two 'hit'? Gastroenterology 1998;114:842-845.
3. Baranova A, Schlauch K, Elariny H, et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with nonalcoholic fatty liver disease. Obes Surg 2007;17:1111-1118.
4. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-421.
5. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:619-638.
6. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274:1379-1383.
7. Selzner N, Selzner M, Odermatt B, et al. ICAM-1 triggers liver regeneration through TNF and IL-6 release in mice. Gastroenterology 2003;124:692-700.
8. Anty R, Bekri S, Luciani N, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol 2006;101:1824-1833.
9. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-1379.
10. Febbraio MA. Gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 2007;117:841-849.
11. Inoue H, Ogawa W, Ozaki M, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004;10:168-174.
12. Peters M, Blinn G, Jostock T, et al. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 2000;119:1663-1671.
13. Klein C, Wü stefeld T, Assmus U, et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 2005;115:860-869.
14. Kovalovich K, Li W, DeAngelis R, et al. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xl. J Biol Chem 2001;276: 26605-26613.
15. Sun Z, Klein AS, Radaeva S, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003;125:202-215.
16. Jin X, Zhang Z, Beer-Stolz D, et al. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 2007;46:802-812.
17. Ramsay AJ, Husband AJ, Ramshaw IA, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994;264:561-563.
18. Selzner N, Selzner M, Jochum W, et al. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatol 2003;39:55-61.
19. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
20. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-867.
21. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-632.
22. Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004;287:G1035-G1043.
23. Okazaki M, Yamada Y, Nishimoto N, et al. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002;84:231-240.
24. Izumi-Nagai K, Nagai N, Ozawa Y, et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 2007;170: 2149-2158.
25. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-1374.
26. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006;87:1-16.
27. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007;132:282-293.
28. Uchiyama Y, Yoshida H, Koike N, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 2008;8:1595-1601.
29. Horiguchi N, Wang L, Mukhopadhyay P, et al. Cell type-dependent pro-and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008;134:1148-1158.
30. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
31. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-79.
32. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3, a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746.
33. Ueki K, Kondo T, Tseng YH, et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci 2004;101: 10422-10427.
34. Jin X, Zimmers TA, Perez EA, et al. Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006;43:474-484.
35. Rotter Sopasakis V, Larsson BM, Johansson A, et al. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 2004;47:1879-1887.
36. Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008;49:1068-1076.
37. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
38. Larter CZ, Yeh MM, Haigh WG, et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol 2008;48:638-647.
39. Ruderman NB, Keller C, Richard AM, et al. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 2006;55(Suppl 2):S48-S54. Review.
40. Tzatsos A, Tsichlis PN. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 2007;282:18069-18082.
41. Hashizume M, Yoshida H, Koike N, et al. Over-produced IL-6 decreases blood lipid levels via up-regulation of VLDLR. Ann Rheum Dis 2010;69:741-746.